Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)

Mayla Gabriela Silva Borba, Fernando Fonseca Almeida Val, Vanderson Sousa Sampaio, Marcia Almeida Araújo Alexandre, Gisely Cardoso Melo, Marcelo Brito, Maria Paula Gomes Mourão, José Diego Brito-Sousa, Djane Baía-da-Silva, Marcus Vinitius Farias Guerra, Ludhmila Abrahão Hajjar, Rosemary Costa Pinto, Antonio Alcirley Silva Balieiro, Felipe Gomes Naveca, Mariana Simão Xavier, Alexandre Salomão, André Machado Siqueira, Alexandre Schwarzbolt, Júlio Henrique Rosa Croda, Maurício Lacerda Nogueira, Gustavo Adolfo Sierra Romero, Quique Bassat, Cor Jesus Fontes, Bernardino Cláudio Albuquerque, Cláudio Tadeu Daniel-Ribeiro, Wuelton Marcelo Monteiro, Marcus Vinícius Guimarães Lacerda, CloroCovid-19 Team
doi: https://doi.org/10.1101/2020.04.07.20056424
Mayla Gabriela Silva Borba
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
2Universidade do Estado do Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Fonseca Almeida Val
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
2Universidade do Estado do Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanderson Sousa Sampaio
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
2Universidade do Estado do Amazonas, Manaus, Brazil
3Fundação de Vigilância em Saúde do Amazonas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcia Almeida Araújo Alexandre
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gisely Cardoso Melo
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
2Universidade do Estado do Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcelo Brito
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
2Universidade do Estado do Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Paula Gomes Mourão
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
2Universidade do Estado do Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Diego Brito-Sousa
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
2Universidade do Estado do Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Djane Baía-da-Silva
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
2Universidade do Estado do Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus Vinitius Farias Guerra
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludhmila Abrahão Hajjar
11Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosemary Costa Pinto
3Fundação de Vigilância em Saúde do Amazonas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Alcirley Silva Balieiro
10Instituto Leônidas & Maria Deane, FIOCRUZ Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felipe Gomes Naveca
10Instituto Leônidas & Maria Deane, FIOCRUZ Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariana Simão Xavier
12Instituto Nacional de Infectologia Carlos Chagas-FIOCRUZ, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandre Salomão
4Hospital Santa Júlia, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
André Machado Siqueira
12Instituto Nacional de Infectologia Carlos Chagas-FIOCRUZ, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandre Schwarzbolt
18Universidade Federal de Santa Maria, Rio Grande do Sul, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Júlio Henrique Rosa Croda
15Faculdade de Medicina da Universidade Federal do Mato Grosso do Sul, Brazil
16Fundação Oswaldo Cruz, Mato Grosso do Sul, Campo Grande, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurício Lacerda Nogueira
17Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marcuslacerda.br@gmail.com
Gustavo Adolfo Sierra Romero
20Universidade de Brasília, Brasília, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Quique Bassat
5ISGlobal, Hospital Clínic–Universitat de Barcelona, Barcelona, Spain
6Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
7ICREA, Barcelona, Spain
8Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain
9Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cor Jesus Fontes
19Universidade Federal de Mato Grosso, Mato Grosso, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernardino Cláudio Albuquerque
14Faculdade de Medicina da Universidade Federal do Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cláudio Tadeu Daniel-Ribeiro
13Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wuelton Marcelo Monteiro
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
2Universidade do Estado do Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus Vinícius Guimarães Lacerda
1Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
2Universidade do Estado do Amazonas, Manaus, Brazil
10Instituto Leônidas & Maria Deane, FIOCRUZ Amazonas, Manaus, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Background There is no specific antiviral therapy recommended for the disease caused by SARS-CoV-2 (COVID-19). Recent publications have drawn attention to the possible benefit of chloroquine (CQ). Our study aimed to comprehensively evaluate the safety and efficacy of two different CQ dosages in patients with established severe COVID-19.

Methods We performed a parallel, double-blinded, randomized, phase IIb clinical trial, aiming to assess safety and efficacy of two different CQ dosages as adjunctive therapy of hospitalized patients with SARS in Manaus, Brazilian Amazon. Eligible participants were allocated to receive orally or via nasogastric tube high dose CQ (600mg CQ twice daily for 10 days or total dose 12g); or low dose CQ (450mg for 5 days, twice daily only on the first day, or total dose 2.7g). In addition, all patients received ceftriaxone and azithromycin. This study was registered with ClinicalTrials.gov, number NCT04323527.

Findings Out of a pre-defined 440 patients sample size, 81 patients were enrolled. The high dose CQ arm presented more QTc>500ms (25%), and a trend toward higher lethality (17%) than the lower dosage. Fatality rate was 13.5% (95%CI=6.9–23.0%), overlapping with the CI of historical data from similar patients not using CQ (95%CI=14.5-19.2%). In 14 patients with paired samples, respiratory secretion at day 4 was negative in only one patient.

Interpretation Preliminary findings suggest that the higher CQ dosage (10-day regimen) should not be recommended for COVID-19 treatment because of its potential safety hazards. Such results forced us to prematurely halt patient recruitment to this arm. Given the enormous global push for the use of CQ for COVID-19, results such as the ones found in this trial can provide robust evidence for updated COVID-19 patient management recommendations.

Funding This study was funded by the Government of the Amazonas State, Farmanguinhos (Fiocruz), SUFRAMA, CAPES, FAPEAM, and federal funds granted by a coalition of Brazilian senators.

Evidence before this study Before the CloroCovid-19 trial began, to our knowledge, there were no published reports of robust clinical studies on the safety and/or efficacy of chloroquine (CQ) and/or hydroxychloroquine (HCQ) for the treatment of COVID-19 during the recent 2020 pandemic. We searched PubMed and also MedRxiv.org (pre-print server for health sciences, without peer review), without any language restrictions and including Chinese publications, for studies published between Dec 2019 and April 5, 2020, using the search terms ‘COVID-19, coronavirus, SARS-Cov-2’. We found three non-randomized studies with limited sample sizes in which (1) HCQ use led to a decrease in SARS-Cov-2 detected in respiratory secretions five days after treatment, together with azithromycin (France, 36 patients); (2) HCQ use shortened time to clinical recovery (China, 62 patients); and (3) CQ was superior to control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, and promoting virus-negative conversion and shortening the disease course (China, 100 patients). We found no published studies comparing different dosages of CQ/HCQ and their thorough safety assessment.

Added value of this study In a larger patient population, we found that a higher dose of CQ for 10 days presented toxicity red flags, particularly affecting QTc prolongation. The limited sample size recruited so far does not allow to show any benefit regarding treatment efficacy, however the trend towards higher fatality associated with the higher dose by day 6 of follow-up resulted in a premature halting of this arm. This is the first double-blinded, randomized clinical trial addressing different dosages of CQ for the treatment of severe patients with COVID-19 in the absence of a control group using placebo. Due to the impossibility of not using the drug recommended at the national level, we used historical data from the literature to infer comparisons for lethality endpoints. Follow-up until day 28 is ongoing with a larger sample size, in which long-term lethality will be better estimated.

Implications of all the available evidence The preliminary findings from CloroCovid-19 trial suggest that the higher dosage of CQ (12 g total dose over 10 days) in COVID-19 should not be recommended because of safety concerns regarding QTc prolongation and increased lethality, in the Brazilian population, and more often in older patients in use of drugs such as azithromycin and oseltamivir, which also prolong QTc interval. Among patients randomized to the lower dosage group (5 days of treatment, total dose 2.7 g), given the limited number of patients so far enrolled, it is still not possible to estimate a clear benefit of CQ in patients with severe ARDS. Preliminary data on viral clearance in respiratory secretions in our confirmed cases are also indicative of little effect of the drug at high dosage. More studies initiating CQ prior to the onset of the severe phase of the disease are urgently needed.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04323527.

Clinical Protocols

https://clinicaltrials.gov/ct2/show/NCT04323527?term=NCT04323527.&draw=2&rank=1

Funding Statement

This study was funded by the Government of the Amazonas State, Farmanguinhos (Fiocruz), SUFRAMA, CAPES, FAPEAM, and federal funds granted by a coalition of Brazilian senators.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All datas are available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted April 11, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb c…
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)
Mayla Gabriela Silva Borba, Fernando Fonseca Almeida Val, Vanderson Sousa Sampaio, Marcia Almeida Araújo Alexandre, Gisely Cardoso Melo, Marcelo Brito, Maria Paula Gomes Mourão, José Diego Brito-Sousa, Djane Baía-da-Silva, Marcus Vinitius Farias Guerra, Ludhmila Abrahão Hajjar, Rosemary Costa Pinto, Antonio Alcirley Silva Balieiro, Felipe Gomes Naveca, Mariana Simão Xavier, Alexandre Salomão, André Machado Siqueira, Alexandre Schwarzbolt, Júlio Henrique Rosa Croda, Maurício Lacerda Nogueira, Gustavo Adolfo Sierra Romero, Quique Bassat, Cor Jesus Fontes, Bernardino Cláudio Albuquerque, Cláudio Tadeu Daniel-Ribeiro, Wuelton Marcelo Monteiro, Marcus Vinícius Guimarães Lacerda, CloroCovid-19 Team
medRxiv 2020.04.07.20056424; doi: https://doi.org/10.1101/2020.04.07.20056424
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)
Mayla Gabriela Silva Borba, Fernando Fonseca Almeida Val, Vanderson Sousa Sampaio, Marcia Almeida Araújo Alexandre, Gisely Cardoso Melo, Marcelo Brito, Maria Paula Gomes Mourão, José Diego Brito-Sousa, Djane Baía-da-Silva, Marcus Vinitius Farias Guerra, Ludhmila Abrahão Hajjar, Rosemary Costa Pinto, Antonio Alcirley Silva Balieiro, Felipe Gomes Naveca, Mariana Simão Xavier, Alexandre Salomão, André Machado Siqueira, Alexandre Schwarzbolt, Júlio Henrique Rosa Croda, Maurício Lacerda Nogueira, Gustavo Adolfo Sierra Romero, Quique Bassat, Cor Jesus Fontes, Bernardino Cláudio Albuquerque, Cláudio Tadeu Daniel-Ribeiro, Wuelton Marcelo Monteiro, Marcus Vinícius Guimarães Lacerda, CloroCovid-19 Team
medRxiv 2020.04.07.20056424; doi: https://doi.org/10.1101/2020.04.07.20056424

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (414)
  • Anesthesia (90)
  • Cardiovascular Medicine (858)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8561)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1749)
  • Geriatric Medicine (167)
  • Health Economics (372)
  • Health Informatics (1242)
  • Health Policy (620)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10299)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (211)
  • Neurology (1677)
  • Nursing (97)
  • Nutrition (251)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (450)
  • Oncology (928)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (113)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (252)
  • Primary Care Research (208)
  • Psychiatry and Clinical Psychology (1768)
  • Public and Global Health (3837)
  • Radiology and Imaging (623)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (167)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)